The Effect of a Plant Protein Isolate on Muscle Protein Synthesis in Humans at Rest and After Resistance Exercise

Sponsor
University of Limerick (Other)
Overall Status
Completed
CT.gov ID
NCT05020808
Collaborator
Marigot Ltd. (Industry), Enterprise Ireland (Other)
33
1
2
9.2
3.6

Study Details

Study Description

Brief Summary

Plant-based proteins contain several amino acids that are essential to signal growth, reconditioning, maintenance and preservation of skeletal muscle mass. This study aims to inform on the nutrient activation of muscle protein synthesis (MPS) by feeding a plant protein isolate equivalent to 0.33 g of protein per kilogram of body mass.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: NEAA
  • Dietary Supplement: PPI
N/A

Detailed Description

Participants: 32 young, healthy men and women aged 18 - 35 years. Intervention: Plant protein isolate (PPI) and nonessential amino acid control (NEAA) Study Design: Block randomised control trial. Two group parallel design. Primary outcome: Myofibrillar fractional synthetic rate (myoFSR).

Preliminary screening/familiarization consists of: medical history, dietary assessment and examination by a medical doctor and a qualified dietician, blood sample to be evaluated for health-related contraindications, body composition measurement by dual energy x-ray absorptiometry (DXA), isokinetic knee extensor strength tests.

Pre-trial: A metered dose of deuterium oxide (5ml/kg) will be ingested and blood and/or saliva (~5ml) samples will be collected pre/post ingestion.

Experimental trial: Blood, saliva and bilateral m.vastus lateralis microbiopsies (~100 mg) collected. A unilateral resistance-training session consisting of knee extensor contractions will be completed. Following exercise cessation participants will ingest 0.33 g/kg body mass of either: a nonessential amino acid formulation or a plant-protein isolate. A saliva sample and a 2nd set of bilateral m.vastus lateralis microbiopsies are collected 3 h postingestion.

Study Design

Study Type:
Interventional
Actual Enrollment :
33 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Block randomized control trial, parallel group designBlock randomized control trial, parallel group design
Masking:
Single (Participant)
Masking Description:
Single blind (participant)
Primary Purpose:
Basic Science
Official Title:
The Effect of a Plant Protein Isolate on Muscle Protein Synthesis in Humans at Rest, and After Resistance Exercise: A Randomized Controlled Trial
Actual Study Start Date :
Sep 14, 2021
Actual Primary Completion Date :
Jun 20, 2022
Actual Study Completion Date :
Jun 20, 2022

Arms and Interventions

Arm Intervention/Treatment
Sham Comparator: Nonessential amino acid formulation (NEAA)

Novel non-essential amino acid blend dosed at 0.33 g/kg body mass in 400 ml of water. Postprandial muscle protein synthesis at rest, and after resistance exercise to be measured by deuterium incorporation in to skeletal muscle sampled by bilateral microbiopsies. Product Number: NEAA56812

Dietary Supplement: NEAA
Food grade mixture of non-essential amino acids in powdered form to be dissolved in water. Supplied by Marigot Ltd, Cork, Ireland

Active Comparator: Plant Protein Isolate (PPI)

Plant protein isolate (Fava bean) dosed at 0.33 g/kg body mass in 400 ml of water. Postprandial muscle protein synthesis at rest, and after resistance exercise to be measured by deuterium incorporation in to skeletal muscle sampled by bilateral microbiopsies. Product Number: FP2011273

Dietary Supplement: PPI
Food grade plant (legume - Fava) protein isolate to be dissolved in water. Supplied by Marigot Ltd, Cork, Ireland
Other Names:
  • Plant Protein Isolate
  • Outcome Measures

    Primary Outcome Measures

    1. Myofibrillar fractional synthetic rate change [4 hours]

      The fractional rate of myofibrillar protein synthesis measured by deuterium incorporation into skeletal muscle sampled by microbiopsy

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 35 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Men and women aged 18 to 35 years
    Exclusion Criteria:
    • Known intolerance to any item contained in the protein products.

    • Blood borne disease risk, current illness or medication that would adversely affect participation

    • Known adverse reaction to venepuncture and/or biopsy

    • Inability to undertake resistance exercise

    • Inability to adhere to protocol guidelines

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Limerick Limerick Munster Ireland V94 T9PX

    Sponsors and Collaborators

    • University of Limerick
    • Marigot Ltd.
    • Enterprise Ireland

    Investigators

    • Principal Investigator: Philip M Jakeman, PhD, University of Limerick
    • Principal Investigator: Robert W Davies, PhD, University of Limerick

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Robert Davies, Principal Investigator, University of Limerick
    ClinicalTrials.gov Identifier:
    NCT05020808
    Other Study ID Numbers:
    • 2020_04_07_EHS
    First Posted:
    Aug 25, 2021
    Last Update Posted:
    Jun 22, 2022
    Last Verified:
    Jun 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Robert Davies, Principal Investigator, University of Limerick

    Study Results

    No Results Posted as of Jun 22, 2022